What question did this study set out to answer?

This research aims to evaluate the safety, tolerability, and preliminary efficacy of DM005 in patients with advanced solid tumors.

First-in-human study of DM005, an anti-EGFR/c-MET bispecific antibody-drug conjugate, in patients with advanced solid tumors.

View Full Paper

Ask AI

Bookmark

This research aims to evaluate the safety, tolerability, and preliminary efficacy of DM005 in patients with advanced solid tumors.
First-in-human dose-escalation trial (NCT 06515990) with intravenous DM005 administration ranging from 0.5 to 6.5 mg/kg Q3W.
Utilization of a classical '3+3' study design to assess safety and preliminary efficacy.
Tumor responses were evaluated according to RECIST v1.1 with a Safety Monitoring Committee overseeing the trial.
A total of 45 patients were enrolled, with no dose limiting toxicities (DLT) observed up to 6.5 mg/kg.
Among 32 evaluable patients, the unconfirmed objective response rate (ORR) was 46.2%, and the disease control rate (DCR) was 84.6%.
The maximum tolerated dose (MTD) was not reached, with most treatment-related adverse events being Grade 1-2.

No takes yet. Share an insight, caveat, or question.

Randomized trial evaluates safety and efficacy of DM005 in patients with advanced solid tumors, suggesting potential benefits.

Yang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark